Related Experiment Videos
[Protein C and plasma serine protease inhibitors in patients with essential hypertension]
J Kłoczko1, M Bielawiec, M Galar
1Kliniki Hematologii AM w Białymstoku.
Polski Tygodnik Lekarski (Warsaw, Poland : 1960)
|December 26, 1991
Insights
Essential hypertension is linked to blood clotting issues. Hypertensive patients show hypercoagulability and impaired fibrinolysis, indicating a higher risk of thrombosis.
Area of Science:
- Cardiovascular Medicine
- Hematology
- Clinical Biochemistry
Context:
- Essential hypertension is a prevalent cardiovascular condition.
- Hemostasis and fibrinolysis play critical roles in cardiovascular health.
- Alterations in coagulation parameters are implicated in hypertensive disease pathology.
Purpose:
- To investigate hemostasis and fibrinolysis parameters in patients with essential hypertension.
- To identify specific coagulation markers associated with hypertension.
Summary:
- This study analyzed plasma protein C, serine protease inhibitors, and other hemostasis parameters in 60 essential hypertension patients.
- Findings revealed decreased protein C and alpha 2-antiplasmin, increased fibrinogen, fibrinopeptide A, WF: Ag, and plasminogen.
- A significant prolongation of euglobulin fibrinolysis time was also observed.
Impact:
- Results suggest a state of hypercoagulability and a fibrinolysis defect in essential hypertension.
- These findings may contribute to understanding the prothrombotic state in hypertensive individuals.
- Highlights potential therapeutic targets for managing thrombotic risk in hypertension.
Abstract:
Plasma protein C and serine protease inhibitors together with some other hemostasis parameters have been determined in 60 patients with essential hypertension. Significant decrease in protein C and alpha 2-antiplasmin levels, increased fibrinogen, fibrinopeptide A, WF: Ag, plasminogen, and prolongation of euglobulin fibrinolysis time have been observed. Results indicate hypercoagulability and fibrinolysis defect in hypertensive patients.